OBJECTIVES

: Most newly approved therapies with oncology indications are designed against a specific mutation or target. Often, genomic testing is required prior to prescribing these novel agents and delays in receiving test results can lead to delay in treatment initiation. This research aimed to assess community oncologists’ perceptions of this new trend.

METHODS

: US-based community oncologist from various geographic locations and practice types were surveyed during live meetings from 2015-2017 using audience response technology. Where appropriate, some questions allowed more than one answer. Survey questions were centered on views regarding genomic testing and challenges in obtaining and interpreting results.

RESULTS

: Almost all respondents, when asked, agreed genomic testing is important in diagnosing and treating cancer patients. While 63% stated they currently and routinely use genomic testing to select appropriate therapy, 31% admitted they will likely start in the very near future. Most surveyed physicians believe that genomic testing ultimately leads to cost savings to the healthcare system. When ordered, 58% limit testing to specific diagnoses. The top 2 barriers to performing genomic testing were: coverage issues (49%), investment in staff time and cost to the practice (18%). The most commonly used tests were the commercially available ones that have specific CPT codes (67%). Using acute myeloid leukemia (AML) as a model for genomic testing, 85% of 142 respondents stated they always perform genomic/mutational analysis on their AML patients. However, 21% of physicians stated that turn-around time was 15 days or more and 47% must send samples to an outside facility.

CONCLUSIONS

: Genomic testing is increasingly being used by community oncologists who view these tests as cost-saving. Payer coverage was identified as the major barrier to these tests. Strategies to decrease the turnaround time are essential to improve access and increase the clinical utility of these tests.